Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes

References

• Hebert J, Riche B, Vogrig A, et al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. 2020 Nov;7(6). DOI:10.1212/NXI.0000000000000883.
   PubMed Web of Science ®Google Scholar
• Vogrig A, Gigli GL, Segatti S, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2020 Jan;267(1):26–35.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008 Apr;7(4):327–340.
   PubMed Web of Science ®Google Scholar
• Didelot A, Honnorat J. Paraneoplastic disorders of the central and peripheral nervous systems. Handb Clin Neurol. 2014;121:1159–1179.
   PubMedGoogle Scholar
• Grativvol RS, Cavalcante WCP, Castro LHM, et al. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Curr Oncol Rep. 2018 Nov 10;20(11):92.
   PubMed Web of Science ®Google Scholar
• Ricken G, Schwaiger C, De Simoni D, et al. Detection methods for autoantibodies in suspected autoimmune encephalitis. Front Neurol. 2018;9:841.
   PubMed Web of Science ®Google Scholar
• Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135–1140.
   PubMed Web of Science ®Google Scholar
• Darnell RB, Posner JB. Paraneoplastic syndromes. Oxford, UK: Oxford University Press; 2011.
   Google Scholar
• Garcia Vicente AM, Delgado-Bolton RC, Amo-Salas M, et al. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1575–1587.
   PubMed Web of Science ®Google Scholar
• Vatankulu B, Yilmaz Aksoy S, Asa S, et al. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes. Rev Esp Med Nucl Imagen Mol. 2016 Jan-Feb;35(1):17–21.
   PubMed Web of Science ®Google Scholar
• Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003 Oct 16;349(16):1543–1554.
   PubMed Web of Science ®Google Scholar
• Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis. Front Neurol. 2019;10:804.
   PubMed Web of Science ®Google Scholar
• Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014 Feb;13(2):167–177.
   PubMed Web of Science ®Google Scholar
• De Graaff E, Maat P, Hulsenboom E, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol. 2012 Jun;71(6):815–824.
   PubMed Web of Science ®Google Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr;15(4):391–404.
   PubMed Web of Science ®Google Scholar
• Graus F, Arino H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014 May 22;123(21):3230–3238.
   PubMed Web of Science ®Google Scholar
• Vogrig A, Bernardini A, Gigli GL, et al. Stroke-like presentation of paraneoplastic cerebellar degeneration: a single-center experience and review of the literature. Cerebellum. 2019 Oct;18(5):976–982.
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J, Valldeoriola F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J Neuroimmunol. 1997 Apr;74(1–2):55–61.
   PubMed Web of Science ®Google Scholar
• Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997 Aug;120(Pt 8):1279–1300.
   PubMed Web of Science ®Google Scholar
• Berzero G, Psimaras D. Neurological paraneoplastic syndromes: an update. Curr Opin Oncol. 2018 Nov;30(6):359–367.
   PubMed Web of Science ®Google Scholar
• Armangue T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016 Apr;73(4):417–424.
   PubMed Web of Science ®Google Scholar
• Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001 Feb;124(Pt 2):437–443.
   PubMed Web of Science ®Google Scholar
• Armangue T, Titulaer MJ, Sabater L, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol. 2014 Mar;75(3):435–441.
   PubMed Web of Science ®Google Scholar
• Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010 Mar;67(3):330–335.
   PubMedGoogle Scholar
• Dalmau J, Furneaux HM, Rosenblum MK, et al. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology. 1991 Nov;41(11):1757–1764.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Gurtekin Y, Dropcho EJ, et al. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol. 2005 Jan;116(1):28–34.
   PubMed Web of Science ®Google Scholar
• Antoine JC, Camdessanche JP. Paraneoplastic neuropathies. Curr Opin Neurol. 2017 Oct;30(5):513–520.
   PubMed Web of Science ®Google Scholar
• Condom E, Vidal A, Rota R, et al. Paraneoplastic intestinal pseudo-obstruction associated with high titres of Hu autoantibodies. Virchows Arch A Pathol Anat Histopathol. 1993;423(6):507–511.
   PubMedGoogle Scholar
• Taverna JA, Babiker HM, Yun S, et al. The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res. 2014;2(1):23.
   PubMedGoogle Scholar
• Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):412–416.
   PubMed Web of Science ®Google Scholar
• Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007 Dec 15;57(8):1473–1480.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012 Feb;64(2):513–522.
   PubMed Web of Science ®Google Scholar
• Lu X, Peng Q, Wang G. The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. Curr Opin Rheumatol. 2019 Nov;31(6):643–649.
   PubMed Web of Science ®Google Scholar
• Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol. 2009 Jun;9(3):336–340.
   PubMed Web of Science ®Google Scholar
• Aarli JA, Stefansson K, Marton LS, et al. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol. 1990 Nov;82(2):284–288.
   PubMed Web of Science ®Google Scholar
• Baggi F, Andreetta F, Antozzi C, et al. Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma. Ann N Y Acad Sci. 1998 May;13(841):538–541.
   Web of Science ®Google Scholar
• Yamamoto AM, Gajdos P, Eymard B, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001 Jun;58(6):885–890.
   PubMed Web of Science ®Google Scholar
• Romi F, Suzuki S, Suzuki N, et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol. 2012 Jul;259(7):1312–1316.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Satoh T, Yasuoka H, et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005 Dec 30;170(1–2):141–149.
   PubMed Web of Science ®Google Scholar
• Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol. 2007 Jun;14(6):617–620.
   PubMed Web of Science ®Google Scholar
• Evoli A. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 2017 Oct;30(5):464–470.
   PubMed Web of Science ®Google Scholar
• Motomura M, Lang B, Johnston I, et al. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997 Mar 20;147(1):35–42.
   PubMed Web of Science ®Google Scholar
• O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988 Jun;111(Pt 3):577–596.
   PubMed Web of Science ®Google Scholar
• Maddison P, Titulaer MJ, Verschuuren JJ, et al. The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. J Neuroimmunol. 2019 Jan 15;326:14–18.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009 Sep 10;27(26):4260–4267.
   PubMed Web of Science ®Google Scholar
• Vural B, Chen LC, Saip P, et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer. 2005 Jun 15;103(12):2575–2583.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011 Mar 1;29(7):902–908.
   PubMed Web of Science ®Google Scholar
• Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handb Clin Neurol. 2016;133:447–466.
   PubMedGoogle Scholar
• Saiz A, Bruna J, Stourac P, et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):404–407.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004 Aug;127(Pt 8):1831–1844.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Parisi JE, McKeon A, et al. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol. 2010 Sep;67(9):1109–1115.
   PubMedGoogle Scholar
• Mandel-Brehm C, Dubey D, Kryzer TJ, et al. Kelch-like protein 11 Antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med. 2019 Jul 4;381(1):47–54.
   PubMed Web of Science ®Google Scholar
• Dubey D, Wilson MR, Clarkson B, et al. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis. JAMA Neurol. 2020 Aug 3;77(11): 1420–1429.
   PubMed Web of Science ®Google Scholar
• Maudes E, Landa J, Munoz-Lopetegi A, et al. Clinical significance of Kelch-like protein 11 antibodies. Neurol Neuroimmunol Neuroinflamm. 2020 May;7(3):e666.
   PubMed Web of Science ®Google Scholar
• De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med. 1993 Dec 1;178(6):2219–2223.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017 Apr;97(2):839–887.
   PubMed Web of Science ®Google Scholar
• Vogrig A, Joubert B, Maureille A, et al. Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. J Neurol. 2019 Feb;266(2):398–410.
   PubMed Web of Science ®Google Scholar
• Figueroa M, Guo Y, Tselis A, et al. Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. JAMA Neurol. 2014 Apr;71(4):495–498.
   PubMed Web of Science ®Google Scholar
• Kimpinski K, Iodice V, Vernino S, et al. Association of N-type calcium channel autoimmunity in patients with autoimmune autonomic ganglionopathy. Auton Neurosci. 2009 Oct 5;150(1–2):136–139.
   PubMed Web of Science ®Google Scholar
• Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000 Sep 21;343(12):847–855.
   PubMed Web of Science ®Google Scholar
• Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010 Aug;9(8):776–785.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011 Feb;69(2):303–311.
   PubMed Web of Science ®Google Scholar
• Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004 Mar;127(Pt 3):701–712.
   PubMed Web of Science ®Google Scholar
• Michael S, Waters P, Irani SR. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2. Pract Neurol. 2020. Jun 28;20(5):377–384.
   PubMedGoogle Scholar
• Irani SR, Vincent A. Voltage-gated potassium channel-complex autoimmunity and associated clinical syndromes. Handb Clin Neurol. 2016;133:185–197.
   PubMedGoogle Scholar
• Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012 Aug;72(2):241–255.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Pittock SJ, McKeon A, et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011 Jun;68(6):733–738.
   PubMedGoogle Scholar
• Lugaresi E, Provini F, Cortelli P. Agrypnia excitata. Sleep Med. 2011 Dec;12(Suppl 2):S3–10.
   PubMed Web of Science ®Google Scholar
• Torres-Vega E, Mancheno N, Cebrian-Silla A, et al. Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology. 2017 Mar 28;88(13):1235–1242.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008 Dec;7(12):1091–1098.
   PubMed Web of Science ®Google Scholar
• Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010 Jun;133(Pt 6):1655–1667.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Armangue T, Planaguma J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019 Jul 17;18(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012 Sep 11;79(11):1094–1100.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010 Jan;9(1):67–76.
   PubMed Web of Science ®Google Scholar
• Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014 Mar;13(3):276–286.
   PubMed Web of Science ®Google Scholar
• Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017 Mar 14;88(11):1012–1020.
   PubMed Web of Science ®Google Scholar
• Van Coevorden-hameete MH, De Bruijn M, De Graaff E, et al. The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain. 2019 Jun 1;142(6):1631–1643.
   PubMed Web of Science ®Google Scholar
• Cui J, Bu H, He J, et al. The gamma-aminobutyric acid-B receptor (GABAB) encephalitis: clinical manifestations and response to immunotherapy. Int J Neurosci. 2018 Jul;128(7):627–633.
   PubMed Web of Science ®Google Scholar
• Bataller L, Galiano R, Garcia-Escrig M, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology. 2010 Jan 19;74(3):265–267.
   PubMed Web of Science ®Google Scholar
• Hoftberger R, Van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 2015 Jun 16;84(24):2403–2412.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011 Nov 1;77(18):1698–1701.
   PubMed Web of Science ®Google Scholar
• Spatola M, Sabater L, Planaguma J, et al. Encephalitis with mGluR5 antibodies: symptoms and antibody effects. Neurology. 2018 May 29;90(22):e1964–e1972.
   PubMed Web of Science ®Google Scholar
• Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011 May;69(5):892–900.
   PubMed Web of Science ®Google Scholar
• Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013 Jan;73(1):120–128.
   PubMed Web of Science ®Google Scholar
• Hara M, Arino H, Petit-Pedrol M, et al. DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology. 2017 Apr 4;88(14):1340–1348.
   PubMed Web of Science ®Google Scholar
• Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017 May 2;88(18):1736–1743.
   PubMed Web of Science ®Google Scholar
• Sepulveda M, Sola-Valls N, Escudero D, et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler. 2018 Nov;24(13):1753–1759.
   PubMed Web of Science ®Google Scholar
• Blaes F, Dharmalingam B. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment. Expert Rev Neurother. 2016 Jun;16(6):641–648.
   PubMed Web of Science ®Google Scholar
• Mitchell WG, Blaes F. Cancer and autoimmunity: paraneoplastic neurological disorders associated with neuroblastic tumors. Semin Pediatr Neurol. 2017 Aug;24(3):180–188.
   PubMed Web of Science ®Google Scholar
• Chew HB, Ngu LH, Keng WT. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD): a case with additional features and review of the literature. BMJ Case Rep. 2011. Mar 1;2011:bcr0220102706.
   PubMedGoogle Scholar
• Jacobson LA, Rane S, McReynolds LJ, et al. Improved behavior and neuropsychological function in children with ROHHAD after high-dose cyclophosphamide. Pediatrics. 2016 Jul;138(1):e20151080.
   Web of Science ®Google Scholar
• Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol. 2017;8:468.
   PubMed Web of Science ®Google Scholar
• Pike M. Opsoclonus-myoclonus syndrome. Handb Clin Neurol. 2013;112:1209–1211.
   PubMedGoogle Scholar
• Korfei M, Fuhlhuber V, Schmidt-Woll T, et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol. 2005 Dec 30;170(1–2):150–157.
   PubMed Web of Science ®Google Scholar
• Berridge G, Menassa DA, Moloney T, et al. Glutamate receptor delta2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology. 2018 Aug 21;91(8):e714–e723.
   PubMed Web of Science ®Google Scholar
• Petit-Pedrol M, Guasp M, Armangue T, et al. Absence of GluD2 antibodies in patients with opsoclonus-myoclonus syndrome. Neurology. 2021 Feb 16;96(7):e1082–e1087.
   PubMed Web of Science ®Google Scholar
• Hero B, Schleiermacher G. Update on pediatric opsoclonus myoclonus syndrome. Neuropediatrics. 2013 Dec;44(6):324–329.
   PubMed Web of Science ®Google Scholar
• Mitchell WG, Wooten AA, O’Neil SH, et al. Effect of increased immunosuppression on developmental outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol. 2015 Jul;30(8):976–982.
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019 Sep;16(9):535–548.
   PubMed Web of Science ®Google Scholar
• Shah S, Dunn-Pirio A, Luedke M, et al. Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med. 2018;2018:2548528.
   PubMed Web of Science ®Google Scholar
• Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016 Aug 1;73(8):928–933.
   PubMed Web of Science ®Google Scholar
• Schafer KH, Klotz M, Mergner D, et al. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J Autoimmun. 2000 Dec;15(4):479–484.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Tanaka M, Onodera O, et al. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci. 1994 Dec 20;127(2):153–158.
   PubMed Web of Science ®Google Scholar
• Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998 Nov;4(11):1321–1324.
   PubMed Web of Science ®Google Scholar
• Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012 May;135(Pt 5):1622–1638.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Cheung NK, et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer. 1995 Jan 1;75(1):99–109.
   PubMed Web of Science ®Google Scholar
• Small M, Treilleux I, Couillault C, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. 2018 Apr;135(4):569–579.
   PubMed Web of Science ®Google Scholar
• Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010 Apr 28;30(17):5866–5875.
   PubMed Web of Science ®Google Scholar
• Planaguma J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015 Jan;138(Pt 1):94–109.
   PubMed Web of Science ®Google Scholar
• Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010 Sep;133(9):2734–2748.
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997 Aug;15(8):2866–2872.
   PubMed Web of Science ®Google Scholar
• Blaes F, Strittmatter M, Merkelbach S, et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol. 1999 Apr;246(4):299–303.
   PubMed Web of Science ®Google Scholar
• Berzero G, Karantoni E, Dehais C, et al. Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789–792.
   PubMed Web of Science ®Google Scholar
• De Jongste AH, Van Gelder T, Bromberg JE, et al. A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro Oncol. 2015 Jan;17(1):145–150.
   PubMed Web of Science ®Google Scholar
• Vernino S, O’Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004 Jan;6(1):55–62.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018 Mar 1;378(9):840–851.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013 Feb;12(2):157–165.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee ST, Byun JI, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. 2016 May 3;86(18):1683–1691.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee ST, Moon J, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016 Oct;13(4):824–832.
   PubMed Web of Science ®Google Scholar